CJC-1295 is a lab-made 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). FDA treats CJC-1295 and CJC-1295 with drug affinity complex (DAC) as two different active substances.3 It is not an FDA-approved drug. FDA’s 2024 evaluation found that none of five CJC-1295-related substances is a component of an FDA-approved drug, and FDA staff recommended against adding any of them to the list of substances pharmacies may use in compounding.3 Its human data come from small, short studies in healthy adults, and FDA found no data on effectiveness for growth hormone deficiency. A company stopped clinical trials in 2006 after a participant died.3 CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.6
CJC-1295 at a glance
What it is
A synthetic analogue of growth hormone-releasing hormone, 29 amino acids long. A version with an added drug affinity complex (DAC) binds to albumin in the blood and lasts longer.3
FDA status
Not FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.1,3
Human evidence
Small placebo-controlled studies in healthy adults that measured hormone levels. FDA identified no effectiveness data for growth hormone deficiency.3
Sport status
FDA’s 2024 evaluation notes that growth hormone secretagogues, including CJC-1295, are prohibited at all times on the World Anti-Doping Agency’s prohibited list.3
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is CJC-1295?
CJC-1295 is a lab-made peptide of 29 amino acids modelled on growth hormone-releasing hormone (GHRH), the brain hormone that prompts the pituitary to release growth hormone.3
FDA’s evaluation distinguishes CJC-1295 from CJC-1295 with drug affinity complex (DAC), which carries an added chemical group that binds albumin in the blood. FDA treats them as different active substances, each with salt forms, and says they are not interchangeable.3
FDA reports that CJC-1295 DAC was first described in 2005 by ConjuChem Biotechnologies, and that interest in CJC-1295 on internet forums has grown since then.3
How is CJC-1295 thought to work?
As an analogue of GHRH, CJC-1295 is intended to stimulate the release of growth hormone. FDA states that published studies show CJC-1295 DAC acts as a growth hormone secretagogue in rodents, but it found no studies establishing whether CJC-1295 without DAC is pharmacologically active.3
FDA notes that the DAC modification is thought to extend the peptide’s life in the body by binding albumin, but could also cause it to bind other proteins and have off-target effects.3
What do human studies show?
FDA’s evaluation describes placebo-controlled studies in healthy adults, published in 2006, in which a CJC-1295 DAC substance raised growth hormone and IGF-1 levels for days after a single exposure.3
Across three published studies, FDA counted 63 healthy adults exposed to it, 87% of them men, and 73% received only one exposure. Reactions where it was given were most common; FDA also lists headache, reactions in which blood vessels widen, increased heart rate and low blood pressure.3
FDA describes reports that a 2006 Phase 2 trial in people with HIV lipodystrophy was stopped after a participant had a fatal heart attack, which the attending physician attributed to underlying coronary artery disease. The data from that trial have not been published.3
FDA found no data on effectiveness for growth hormone deficiency and no safety information in children.3
What the evidence base contains
Controlled human trial Two placebo-controlled studies in healthy adults published in 2006, in which most participants received one or a few exposures to a CJC-1295 DAC substance and growth hormone and IGF-1 levels were measured.3
Small, short, or incompletely reported human study FDA counted 63 healthy adults, 87% of them men, exposed to a CJC-1295 DAC substance across three published studies; 73% received a single exposure.3
Animal or laboratory research Animal studies in which a CJC-1295 DAC substance acted as a growth hormone secretagogue, and toxicology studies in rats and dogs that showed bleeding, inflammation and tissue death where it was given.3
No. FDA’s evaluation, dated November 15, 2024, states that none of the five CJC-1295-related substances is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for any of them.3
FDA staff evaluated the five substances for the 503A bulks list, the list of substances that pharmacies may use in compounding, for growth hormone deficiency. They concluded that the balance of criteria weighs against adding any of them, citing poor characterization, unclear history of use, safety concerns from animal studies and a lack of effectiveness data.3
A Federal Register notice announced that FDA’s Pharmacy Compounding Advisory Committee would discuss CJC-1295-related substances at its December 4, 2024 meeting. FDA’s evaluation states that FDA will not issue a final determination until the committee’s input has been considered.3,4
FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.5,6
Timeline
CJC-1295 DAC is first described in the scientific literature, according to FDA’s evaluation.3
ConjuChem withdraws CJC-1295 DAC from clinical trials after a participant’s death, according to FDA’s evaluation.3
A Federal Register notice announces the December 4, 2024 advisory-committee meeting that will discuss CJC-1295-related substances.4
FDA staff date their evaluation recommending against adding CJC-1295-related substances to the 503A bulks list.3
FDA’s Pharmacy Compounding Advisory Committee meets to discuss CJC-1295-related substances.3,4
FDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns.1
What is still unknown?
Whether CJC-1295 has any clinical benefit: FDA found no effectiveness data for growth hormone deficiency.3
Its long-term safety, which FDA says is unknown, and its safety in children, for which FDA found no information.3
What is in products sold under the name: FDA found inconsistent naming and notes that it is often unclear which form is meant.3
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,3
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for CJC-1295: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for CJC-1295 are the records PeptideScanner has selected and published, not every registration or paper about CJC-1295. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.↗↗↗
What the reviewed sources report
The studies reported sustained growth hormone and IGF-I responses, including preserved hormone pulsatility. They do not establish clinical benefit for injury recovery, body composition or aging, or long-term safety.↗↗
What remains unresolved?
Which findings apply to the exact molecular form and formulation being discussed?↗↗
Do controlled studies demonstrate patient-important benefits and adequately assess longer-term harms?↗↗
FDA assessment dated November 15, 2024 · Read September 15, 2026 · Preserved version 1
FDA's dated evaluation of five CJC-1295-related bulk substances. The briefing distinguishes DAC and non-DAC forms and is an advisory-stage assessment, not a final compounding rule. FDA document ↗
Which human evidence applies?
FDA describes the published studies as short studies of DAC forms in healthy adults. It identifies the 2009 proteomic report as a subset of the earlier Ionescu and Frohman study, rather than an independent participant cohort. FDA pp. 40, 42 ↗
What adverse effects were reported?
FDA reports injection-site reactions, headache, flushing and transient blood-pressure changes in the early studies. Limited exposure in healthy adults cannot establish longer-term safety or safety in growth hormone deficiency. FDA pp. 40, 41, 42 ↗
Why the terminated trial matters
FDA cites anecdotal reports of a death during a terminated HIV-lipodystrophy trial and states that its results were unpublished. This is an agency account of those reports, not proof that CJC-1295 caused the death. FDA pp. 40 ↗
Scope, source pin and remaining work
This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.
Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.123
Bottom line from this bounded source set
The studies reported sustained growth hormone and IGF-I responses, including preserved hormone pulsatility. They do not establish clinical benefit for injury recovery, body composition or aging, or long-term safety.12
Reviewed study record
Early pharmacology trials in healthy adults
Design
Two blinded randomized placebo-controlled studies assessed pharmacokinetics and hormone responses over 28 and 49 days.1
Population
Participants were healthy adults aged 21–61; the abstract does not state their total number.1
Outcomes reported
Growth hormone and IGF-I concentrations increased for several days. The report recorded no serious adverse reactions.1
Limitations
Short-term hormone changes are surrogate measurements. No serious reactions in these studies does not establish safety over longer exposure or in other populations.1
Reviewed study record
Growth-hormone pulsatility
Design
A before-and-after physiology study measured overnight hormone secretion before and one week after exposure.2
Population
The participants were healthy men aged 20–40; the abstract does not state their total number.2
Outcomes reported
Mean and trough growth hormone levels and IGF-I increased, while pulse frequency and magnitude were unchanged.2
Limitations
The report describes an albumin-binding preparation and physiological endpoints. It does not establish improvement in a clinical condition or comparative long-term safety.2
Reviewed study record
Exploratory serum-protein biomarkers
Design
A before-and-after serum analysis compared samples before exposure and one week afterward.3
Population
Eleven healthy young adult men contributed samples.3
Outcomes reported
The authors identified changes in several protein spots and an association between one spot and IGF-I levels. These were proposed biomarkers.3
Limitations
This small exploratory analysis measured proteins, not clinical benefit. The selected abstract alone does not establish participant overlap; the companion FDA assessment supplies that context.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2005-1536. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2006-1702. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.ghir.2009.03.001. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The tested substance may not match every marketed name
FDA’s December 2024 briefing considered several CJC-1295 and DAC forms separately. The limited clinical reports appeared to involve a DAC active moiety with incompletely specified form; other nominated forms lacked equivalent clinical information. FDA PDF pp. 46, 50 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Hormone changes in healthy adults did not establish treatment benefit
The reviewed reports involved healthy adults, not patients with growth-hormone deficiency, and did not measure key clinical outcomes such as body-composition change or height velocity. FDA did not consider them evidence of effectiveness for that condition. FDA PDF pp. 50 ↗
The safety sample was small and mostly short exposure
FDA described 63 exposed participants, predominantly men, with most receiving a single exposure. That evidence did not characterize long-term safety or pediatric use. FDA PDF pp. 46 ↗
Adverse events need careful attribution
The briefing describes injection-site and systemic reactions, including heart-rate and blood-pressure effects. It also discusses a death attributed to coronary disease in an unpublished trial account; the document does not prove CJC-1295 caused that death. FDA PDF pp. 46 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary reports of administered CJC-1295 in people, including pharmacology and secondary analyses; animal, cell, analytical-method, review and online-discourse records retained as exclusions from this human-administration subset. This is not a claim that excluded records have no information value.
33 retrieved · 3 included · 30 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"CJC-1295"[Title/Abstract] OR "CJC 1295"[Title/Abstract]
Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.
Showing 25 of 33 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 19386527 — include: Original human administration or secondary human-sample report; full appraisal and study-family reconciliation are separate from this eligibility decision. FDA briefing PDF page 42 (printed page 38) identifies the eleven men in Sackmann-Sala 2009 as a subset of Ionescu and Frohman 2006; these reports are not independent cohorts. Study families: CJC-1295-2006-pulsatility-cohort.Official cohort relationship source ↗.
PubMed 17018654 — include: Original human administration or secondary human-sample report; full appraisal and study-family reconciliation are separate from this eligibility decision. FDA briefing PDF page 42 (printed page 38) identifies the eleven men in Sackmann-Sala 2009 as a subset of Ionescu and Frohman 2006; these reports are not independent cohorts. Study families: CJC-1295-2006-pulsatility-cohort.Official cohort relationship source ↗.
PubMed 16352683 — include: Original human administration or secondary human-sample report; full appraisal and study-family reconciliation are separate from this eligibility decision. Study families: CJC-1295-2006-ascending-studies-linkage-unresolved.
PubMed 42578445 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 42395176 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 42160466 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 42123471 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 42021992 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 41966639 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 41880199 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 41490200 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 41476424 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
PubMed 41138283 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
PubMed 38197510 — exclude: Analytical method with administration samples for other peptides; no CJC-1295 human administration reported in the inspected abstract.
PubMed 37806509 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
PubMed 38716080 — exclude: Analytical method with administration samples for other peptides; no CJC-1295 human administration reported in the inspected abstract.
PubMed 35298973 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
PubMed 34736642 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
PubMed 34665524 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
PubMed 32971474 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
PubMed 30938069 — exclude: Equine analytical or administration research, outside the human-administration subset.
PubMed 30489688 — exclude: Equine analytical or administration research, outside the human-administration subset.
PubMed 27710891 — exclude: Internet-forum research describes reported use and discourse, without independently verified CJC-1295 exposure or clinical treatment outcomes; retained as a possible separate non-official-source research lead.
PubMed 26879649 — exclude: CJC-1295 administration described in rodents; the human administration example was a different GHRH product.
PubMed 26771670 — exclude: Internet-forum research describes reported use and discourse, without independently verified CJC-1295 exposure or clinical treatment outcomes; retained as a possible separate non-official-source research lead.
ClinicalTrials.gov search
ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
Other registries and unregistered studies are outside this search.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT00267527 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT00267527.
FDA search
Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
products.active_ingredients.name:"CJC-1295" OR products.active_ingredients.name:"CJC 1295"
This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of CJC-1295?
Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
PubMed bibliography
Publication composition
1 of 9 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 1
Bibliography fields unavailable here for 8 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
10
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 10 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295.
PubMed lists PMID 42876013 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-14 (day precision). PeptideScanner associated the retained record with the identity slug cjc-1295. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.
Selected records span November 18, 2010 to October 15, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PubMed lists PMID 42876013 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-14 (day precision). PeptideScanner associated the retained record with the identity slug cjc-1295. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 19386527 at 2026-07-30T18:28:26.873Z. PubMed recorded a metadata revision date of 2025-05-29 and an Entrez history date of 2009-04-24. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
The Federal Register published notice 2024-24828, attributed to FDA and its parent HHS department, on 2024-10-25. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to CJC-1295.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 30938069 at 2026-07-30T20:34:12.987Z. PubMed recorded a metadata revision date of 2020-01-13 and an Entrez history date of 2019-04-03. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 30489688 at 2026-07-30T20:43:12.045Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2018-11-30. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 17018654 at 2026-07-30T21:09:06.872Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2006-10-05. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 16352683 at 2026-07-30T21:09:05.761Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2005-12-15. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 26771670 at 2026-07-30T21:35:57.020Z. PubMed recorded a metadata revision date of 2016-12-30 and an Entrez history date of 2016-01-16. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 21204297 at 2026-07-30T21:38:23.138Z. PubMed recorded a metadata revision date of 2016-05-11 and an Entrez history date of 2011-01-05. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 15817669 at 2026-07-30T22:26:16.765Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2005-04-09. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗